Press Release / NEWS / IASO，IASO Bio，IASO Biotherapeutics，IASO Biopharma，CT103A， CAR-T， cell therapy，dual-targeted CAR-T

NEWS

292024-02

IASO Bio’s Equecabtagene Autoleucel for Refractory Myasthenia Gravis (MG) Case Report Published in EMBO Molecular Medicine
012024-02

Promising Clinical Results on the World’s First Use of BCMA CAR-T to Treat Immune Mediated Necrotizing Myopathy (IMNM) Published on the Proceedings of the National Academy of Sciences (PNAS)
042024-01

IASO BIO Announces New Development Partnership with Umoja Biopharma to Develop Ex Vivo and In Vivo Cell and Gene Therapies
122023-12

IASO Bio and Innovent Present New Data of FUCASO® (Equecabtagene Autoleucel) for Multiple Myeloma Patients in Oral Presentation at ASH 2023
282023-09

IASO Bio Presents Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023
102023-07

IASO Bio and Innovent Announce the NMPA Approval of the NDA for Equecabtagene Autoleucel, the World's First Fully-human BCMA CAR-T Therapy, for the Treatment of RRMM
102023-07

IASO Bio Receives FDA Approval of IND Application for IASO-782 for Treatment of Autoimmune Disease
012023-07

IASO Bio and Innovent Updated Efficacy and Safety Clinical Data of Equecabtagene Autoleucel（BCMA CAR-T Cell Therapy）for Multiple Myeloma at the 2023 ASCO Annual Meeting
062023-04

IASO Bio’s partner Cabaletta Receives FDA Clearance of IND Application for CABA-201 for Treatment of SLE
132023-02

IASO Bio Announces CT103A Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track (FT) Designations by the FDA

Copyright © 2023 南京驯鹿生物技术股份有限公司　　　　苏ICP备2021047135号　　　　 Privacy Policy　|　Terms of Use